{"id":"W4365811156","doi":"10.1002/ehf2.14363","title":"Optimizing Outcomes in Heart Failure: 2022 and Beyond","year":2023,"lang":"en","type":"review","venue":"ESC Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"National Heart, Lung, and Blood Institute; Respicardia; American Regent; Abbott Vascular; National Institutes of Health; I.M. Sechenov First Moscow State Medical University; Universidade do Porto; Vifor Pharma; Rigshospitalet; MyoKardia; Novo Nordisk; Medizinischen Hochschule Hannover; University of Glasgow; Pfizer; Moderna; National and Kapodistrian University of Athens; Universidad de Navarra; Impulse Dynamics; Sarepta Therapeutics; Cytokinetics; Alnylam Pharmaceuticals; University of Cyprus; Linköpings Universitet; Amgen; European Society of Cardiology; Westfälische Wilhelms-Universität Münster; Boston Scientific Corporation; Baxter Healthcare Corporation; Cyprus University of Technology; King's College London; Daiichi Sankyo Europe; Servier; Gilead Sciences; Relypsa; Università degli Studi di Pavia; Cairo University; Sanofi; Sanofi Pasteur; Universitair Medisch Centrum Groningen; Celladon Corporation; LivaNova; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Guideline; Heart failure; Intensive care medicine; Quality (philosophy); Health care; Quality of life (healthcare); Best practice; Nursing; Cardiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05475305,0.001852163,0.002135978,0.001626719,0.002375259,0.01092484,0.002539022,0.01138791,0.0102409],"category_scores_gemma":[0.0275152,0.0005521307,0.00243468,0.002115534,0.004905268,0.01342606,0.008657587,0.01514839,0.003753603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007751032,"about_ca_system_score_gemma":0.0466464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008374124,"about_ca_topic_score_gemma":0.009619382,"domain_scores_codex":[0.9838644,0.008236365,0.001254223,0.0007544445,0.003569129,0.002321367],"domain_scores_gemma":[0.9709282,0.01160151,0.001280608,0.001235893,0.006165873,0.008787952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003192991,0.0004065879,0.002926176,0.003307599,0.0001517846,0.0002710326,0.001947257,0.001570196,0.000779679,0.09285509,0.2921889,0.6032764],"study_design_scores_gemma":[0.0001550446,0.0009006779,0.009229364,0.01156999,0.0001316782,0.0003668216,0.003122952,0.001441648,0.0004961961,0.1404282,0.8319609,0.0001964072],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.003124489,0.0946638,0.006750426,0.859597,0.01740324,0.0002035822,0.0004547599,0.0003067825,0.0174959],"genre_scores_gemma":[0.105037,0.258589,0.06282842,0.5186427,0.03780802,0.001474001,0.002488046,0.0004744762,0.01265847],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.05475305,"threshold_uncertainty_score":0.2895653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03891397122767665,"score_gpt":0.3339422766952516,"score_spread":0.2950283054675749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}